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Abstract
Objectives: The purpose of this study was to assess differences in the outcomes of youth with schizophrenia-spectrum
disorders (SCZ-S) and psychotic disorder not otherwise specified (PsyNOS) during early antipsychotic treatment.
Methods: The study was a prospective, naturalistic, inception cohort study of youth £ 19 years old with SCZ-S (schizo-
phrenia, schizoaffective disorder, schizophreniform disorder) or PsyNOS (PsyNOS, brief psychotic disorder) and £ 24
months of lifetime antipsychotic treatment receiving clinician’s choice antipsychotic treatment. Baseline demographic,
illness and treatment variables, and effectiveness outcomes were compared at 12 weeks last-observation-carried-forward
across SCZ-S and PsyNOS patients, adjusting for significantly different baseline variables.
Results: Altogether, 130 youth with SCZ-S (n= 42) or PsyNOS (n= 88), mostly antipsychotic naı¨ve (76.9%), were prescribed
risperidone (47.7%), olanzapine (19.2%), aripiprazole (14.6%), quetiapine (11.5%), or ziprasidone (6.9%). Compared with
those with PsyNOS, SCZ-S youth were older (16.4– 2.1 vs. 14.8– 3.2, p= 0.0040), and less likely to be Caucasian (19.1% vs.
42.5%, p= 0.009). At baseline, SCZ-S patients had significantly higher Clinical Global Impressions-Severity (CGI-S) scores
(6.0– 0.9 vs. 5.5– 0.8, p= 0.0018) and lower Children’s Global Assessment Scale (CGAS) scores (29.6– 9.2 vs. 36.1– 8.9,
p= 0.0002) and were more likely to be in the severely ill CGAS group (i.e., CGAS£ 40). SCZ-S and PsyNOS patients did not
differ regarding all-cause discontinuation (40.5 vs. 40.3%. p= 0.49), discontinuation because of adverse effects (12.2% vs.
12.4%, p= 0.97), or nonadherence (29.3% vs. 30.9%, p= 0.88), but somewhat more SCZ-S patients discontinued treatment for
inefficacy (19.5% vs. 7.4%, p= 0.063). CGI-S and CGAS scores improved significantly in both diagnostic groups ( p= 0.0001,
each). Adjusting for baseline differences, PsyNOS patients experienced significantly better CGI-I improvement (CGI-I) scores
( p= 0.012) and more frequently reached higher categorical CGAS group status ( p= 0.021) than SCZ-S patients.
Conclusions: Both youth with SCZ-S and those with PsyNOS experienced significant improvements with clinician’s choice
antipsychotic treatment. However, treatment discontinuation was common within 12 weeks, with greater inefficacy-related
discontinuation in the SCZ-S group, whereasCGI-I andCGAS score-based improvements were greater in the PsyNOSgroup.
1Research Unit for Child and Adolescent Psychiatry, Psychiatric Hospital, Aalborg University Hospital, Denmark.
2The Zucker Hillside Hospital, Psychiatry Research, North Shore–Long Island Jewish Health System, Glen Oaks, New York.
3University Clinics of Child and Adolescent Psychiatry, University of Zurich, Switzerland.
4Hofstra North Shore-LIJ School of Medicine, Hempstead, New York.
5Albert Einstein College of Medicine, Bronx, New York.
6The Feinstein Institute for Medical Research, Manhasset, New York.
7Clinical Psychology and Epidemiology, Department of Psychology, University of Basel, Switzerland.
8Department of Child and Adolescent Psychiatry, University of Zurich, Switzerland.
This study was conducted at The Zucker Hillside Hospital, Psychiatry Research, North Shore–Long Island Jewish Health System, Glen Oaks, New York.
Funding: This work was partially supported by the National Institute of Mental Health Advanced Center for Services and Intervention Research, The
Zucker Hillside Hospital (P30MH090590).
Ditte L. Vernal’s research rotation at the Zucker Hillside Hospital was supported by the Research Unit for Child and Adolescent Psychiatry,
Psychiatric Hospital and the Psychiatric Research Fund, North Denmark Region as well as by Aarhus University.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
Volume 25, Number 7, 2015
ª Mary Ann Liebert, Inc.
Pp. 535–547
DOI: 10.1089/cap.2014.0164
535
Introduction
Schizophrenia and other psychotic disorders are consid-ered among the most severe mental disorders. Approximately
5–15% of patients with schizophrenia have an onset prior to age 18,
defined as ‘‘early onset’’ (Schimmelmann et al. 2013a). Early onset
psychotic disorders are relatively rare, but usually quite severe
(Rapado-Castro et al. 2010), with research pointing to worse out-
comes and prognosis for children and adolescents with psychotic
disorders, especially schizophrenia, compared with adults (Clem-
mensen et al. 2012). More children and adolescents present with
adverse premorbid signs, such as neurocognitive deficits and poor
social adjustment, as well as negative prognostic signs at onset, such
as cognitive impairment, high level of negative symptoms, and in-
sidious onset (Hassan and Taha 2011; Schimmelmann et al. 2013b).
Until a few decades ago, research on psychotic disorders in
children and adolescents was scarce. Fortunately, knowledge about
and research on early-onset schizophrenia have increased in the
past decades. Data have emerged supporting the validity of the
diagnosis in this age group (Maziade et al. 1996; Asarnow 2005;
Helgeland and Torgersen 2005), and significant antipsychotic ef-
ficacy has been demonstrated in short-term placebo-controlled
trials (Correll et al. 2011b; Kendall et al. 2013; McClellan and
Stock 2013; Schimmelmann et al. 2013a). So far, randomized
controlled trials (RCTs), guidelines, and long-term follow-up
studies have primarily focused on early onset schizophrenia, and
although this is the most severe psychotic disorder, other psychotic
disorders are more common, and most youth presenting with psy-
choses are diagnosed with other disorders than schizophrenia. The
child and adolescent first-episode psychosis study (CAFEBS)
found psychosis not otherwise specified (PsyNOS) to be the most
common psychosis-spectrum diagnosis, affecting 35.5% of their
sample at baseline (Castro-Fornieles et al. 2007). Relatively limited
research is available on the epidemiology, clinical characteristics,
and outcome of PsyNOS. Although many clinical studies include
patients with PsyNOS (Wozniak et al. 2008; Rapado-Castro et al.
2010; Swadi et al. 2010; Hassan and Taha 2011), studies rarely
specify the outcome for different types of psychotic disorders, but
either focus solely on schizophrenia or treat all psychotic disorders
as one group. Moreover, trials just focusing on patients with Psy-
NOS are lacking. Therefore, treatment response and outcomes for
patients with PsyNOS are much less known than are outcomes for
patients with schizophrenia.
Because patients with PsyNOS already present with supra-
threshold psychosis, they can be considered a particular high-risk
population for the development of schizophrenia (Correll et al.
2008). Notably, PsyNOS is one of the least stabile diagnoses in the
psychotic spectrum, but study results vary considerably. Studies in
adults have shown that 25–73% will transition to other severe
mental disorders, whereas others will recover or continue to ful-
fill PsyNOS criteria (Sivakumar and Chandrasekaran 1993; Cha-
turvedi and Sahu 1986; Schwartz et al. 2000; Sajith et al. 2002;
Schothorst et al. 2006; Rahm and Cullberg 2007; Subramaniam
et al. 2007; Salvatore et al. 2009; Kingston et al. 2013).
Studies in the child and adolescent population have been in-
conclusive regarding diagnostic stability. Some found diagnostic
stability as low as 7.7% (Correll et al. 2005), 11.8% (Castro-
Fornieles et al. 2011), or 16.7% (Fraguas et al. 2008), and transition
rates to other severe mental disorders as high as 88% (Castro-
Fornieles et al. 2011), whereas others found no transition even after
several years of follow-up (McClellan and McCurry 1999a). Re-
gardless of the rates and direction of diagnostic transition, PsyNOS
is a serious condition in and of itself. McClellan and McCurry
found 38% of youth with PsyNOS to be chronically impaired after 2
years; 75% were on psychotropic medications and only 13% were
in regular school or work (McClellan and McCurry 1999). Another
study of 26 adolescents with PsyNOS or brief psychosis found that
20% had full remission at 6 months follow-up, but 38% had tran-
sitioned to other, more severe disorders (schizophrenia, schi-
zoaffective or bipolar disorder with psychosis) (Correll et al. 2008).
Although it is well established that patients with schizophrenia
have a worse prognosis than those with other psychotic disorders
with an early onset as recently summarized (Clemmensen et al.
2012), there remains a gap in the literature concerning how children
and adolescents with PsyNOS differ from those with schizophrenia-
spectrum disorders in terms of symptom severity and functioning
at baseline, as well as treatment acceptance and responsiveness.
Moreover, the generalizability of the efficacy observed in selected
samples consenting to participate in RCTs to populations treated
in general practice settings is less clear. Furthermore, because
more chronically ill patients are overrepresented in RCTs, very
little is known about outcomes in youth with short illness duration
or even naı¨ve to antipsychotic treatment (Sikich et al. 2008; Arango
et al. 2009).
Therefore, the present study aimed at investigating baseline
differences and short-term outcomes of antipsychotic treatment in
children and adolescents with schizophrenia-spectrum disorders
(SCZ-S) and psychotic disorder not otherwise specified (PsyNOS)
in a naturalistic setting. Because early improvement in patients with
schizophrenia-spectrum disorders is associated with later remission
and outcome (Emsley et al. 2007), studies on the short-term
progress are important. Based on the literature, we hypothesized
that children and adolescents with early- onset schizophrenia would
be more severely impaired and less responsive to antipsychotic
treatment than patients with PsyNOS.
Methods
Study setting and design
Data for this study were collected as part of the Second-Genera-
tion Antipsychotic Treatment Indications, Effectiveness and Toler-
ability in Youth (SATIETY) study, a naturalistic inception cohort
study of antipsychotic treatment in youth with psychotic, mood, or
aggressive spectrum disorders (Correll et al. 2009). Patients were
recruited from the child and adolescent inpatient and outpatient
services at the Zucker Hillside Hospital, Glen Oaks (Queens), New
York, from December 2001 until September 2007. The study was
approved by the North Shore–Long Island Jewish Health System
Institutional Review Board, and written informed consent/assent for
the study as well as the publication of results was signed by all
participants or their legal guardians. The design of the study has been
described in detail previously (Correll et al. 2009); only pertinent
aspects for the current study are detailed in this article.
Inclusion criteria were: 1) Being 4–19 years of age; 2) having a
psychiatric illness prompting antipsychotic initiation; and 3) con-
sent and baseline anthropometric/biochemical assessments ob-
tained within £ 7 days of the present antipsychotic initiation.
Patients were considered antipsychotic naı¨ve if they had £ 1 week
of previous antipsychotic exposure. Patients who had been exposed
to antipsychotics, but who had a treatment gap of > 4weeks, were
dubbed ‘‘patients with antipsychotic history.’’ Patients were con-
sidered antipsychotic switchers if they were moved to another an-
tipsychotic either overlapping with the prior antipsychotic or within
5 half-lives of stopping the prior antipsychotic.
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Exclusion criteria were: 1) Treatment with more than one anti-
psychotic; 2) active/past eating disorder; 3) biochemical evidence
of thyroid dysfunction; 4) acute medical/neurologic disorders; 4)
pregnancy/breastfeeding; 5) being wards of the state (as research
consent by a public agency representative within 1 week was un-
likely); and 6) leaving the catchment area within < 4 weeks.
Inclusion criteria for the current analyses were the subsample of
the full SATIETY study with SCZ-S disorders (i.e., schizophrenia,
schizoaffective disorder, schizophreniform disorder) or PsyNOS
(i.e., psychotic disorder not otherwise specified, brief psychotic
disorder) who had < 24 months of lifetime antipsychotic exposure
and who were not started on clozapine. These two groups were
compared at baseline and 12 week end-point. Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnoses
were made based on a review of all clinical chart information, as
well as an interview of the youth and caregiver (American Psy-
chiatric Association 1994). To qualify for PsyNOS, several possi-
bilities existed: 1) Only one A criterion symptom (other than
bizarre delusions, running commentary, or at least two voices
communicating with each other); 2) fulfilling A criteria but without
presence of distress or functional impairment; or 3) duration of
symptoms fulfilling criteria between 1 week and < 4 weeks. Ac-
cordingly, brief psychotic disorder was subsumed under PsyNOS if
the duration was at least 1 week, whereas psychotic disorder sec-
ondary to a medical disorder or substance use did not count as
PsyNOS.
Treatment
Antipsychotic treatment was initiated as part of clinician’s
choice. Only after the antipsychotic choice wasmade by the treating
clinician was written informed consent/assent for participation in
the study obtained. Dosing, prescription of co-medications and
other treatment changes were all performed by the patient’s treating
clinician based on clinical need.
Assessments
All assessments were conducted by medical doctors trained and
supervised byC.U.C., with regular quality control to avoid rater drift.
Baseline
The following baseline assessments, conducted as part of the
SATIETY study, were analyzed in the current study: Primary and
comorbid psychiatric diagnoses (based on clinical chart informa-
tion as well as patient and caregiver interview by study personnel,
using DSM-IV criteria), ethnicity and past treatment history as-
sessed by chart review, discussion with treatment providers, and
clinical interview of the patient/caregiver. Socioeconomic status
(SES) was categorized according to Hollingshead (Hollingshead
and Redlich 1958), ranging from 1 (highest) to 5 (lowest). Post-
pubertal status (Tanner stages 3–5) was determined through in-
spection and interview of the patient and/or caregiver. Subject
reports of adverse events were recorded by the investigators with a
modified version of the Treatment Emergent Symptoms Scale
(TESS)(Guy 1976). Fasting blood samples were used to assess
glucose, insulin, Homeostasis Model Assessment of Insulin Re-
sistance (HOMA-IR), total cholesterol, low- and high-density li-
poprotein cholesterol (LDL-C and HDL-C), triglycerides, and
prolactin. Furthermore, the Simpson–Angus Ratings Scale (SARS)
(Simpson and Angus 1970), Barnes Akathisia Rating Scale (BARS)
(Barnes 1989), and Abnormal Involuntary Movement Scale (AIMS)
(Guy 1976) were used to rate extrapyramidal side effects, akathisia
and dyskinesia, respectively.
The Clinical Global Impressions (CGI) scale (Guy 1976) was
used to assess severity (CGI-S) and improvement (CGI-I). The
CGI-S measures symptomatology on a scale from 1 (normal, not at
all ill) to 7 (extremely ill). The CGI-I measures improvement on a
similar seven point scale, ranging from 1 (very much improved) to
7 (very much worse). A CGI-I score of 4 indicates ‘‘no change.’’
The child version of the Global Assessment of Functioning Scale,
the Children’s Global Assessment Scale (CGAS) (Shaffer et al.
1983) was used to assess symptomatology as well as psychosocial
functioning. The CGAS is a numeric scale ranging from 0 to 100,
with higher scores indicating better functioning. CGAS ratings are
independent of specific psychiatric diagnoses.
Follow-up
CGAS, CGI-I, CGI-S, detailed medication information (adher-
ence, as reported by the patients and caregivers, discontinuation,
reasons for discontinuation), and adverse affects were assessed at
monthly follow-up assessments. Additionally, antipsychotic blood
levels were measured as an objective measure of nonadherence.
Patients were considered partially nonadherent when deemed to be
taking < 70% of the prescribed medication based on interview, and
were considered nonadherent if they stopped the antipsychotic
against medical advice for > 5 half lives of the antipsychotic or
when antipsychotic blood levels were not measurable.
Outcomes
Co-primary outcomes for the current study were CGI-I based
global improvement and CGAS based categorical outcomes defining
severe illness/functional levels as CGAS scores £50, moderate as
51–70, and mild as > 70 as suggested in a recent review on the
outcome of early-onset schizophrenia (Clemmensen et al. 2012).
Secondary outcomes included change in CGI-S score, CGI-S
end-point score, CGI-I based response (defined asmuch or verymuch
improved), change in CGAS, and CGAS end-point. Frequency of all-
cause discontinuation and specific-cause discontinuation, aswell as the
frequency and severity of adverse events, were also analyzed.
Statistical analyses
Baseline data, length of inpatient stay, medication adherence,
and discontinuation- related outcomes were compared across the
two diagnostic groups in the full intent-to-treat (ITT) sample
(n = 130). In addition, the two diagnostic groups were also com-
pared using the modified ITT (mITT) sample composed of patients
with more than one postbaseline assessment (n= 106, 81.5% of the
entire sample), using last-observation-carried-forward (LOCF)
analyses. These analyses included baseline data, treatment vari-
ables, and CGI and CGAS related outcomes, as well as side effect
related outcomes.
For the majority of patients who did not return for any follow-up
visits, medication information was available through hospital re-
cords. Seven patients were lost to follow-up without medication
information or because they never started the antipsychotic because
of family choice.
Group comparisons at baseline were performed using v2 tests, t
tests, Fisher’s exact test, or Wilcoxon rank sum tests as per data type
and distribution. Because this was a nonrandomized study, all sta-
tistical tests of outcome comparisons were adjusted for variables,
which differed significantly ( p< 0.05) across the two diagnostic
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groups at baseline in the mITT sample. All analyses were two sided
with a set at 0.05 and conducted using Stata12. Prospective outcomes
based on continuous variables were analyzed with linear regression,
binary outcomes with logistic regression and categorical CGAS
outcome were analyzed using ordered logistic regression analysis.
Results
Patient flow
During the study period, 853 youth were started on an antipsy-
chotic. Of these, 675 (79.1%) were excluded because they had
primary diagnoses other than SCZ-S or PsyNOS. Of the remaining
211 subjects, 74 (35.1%) were excluded because they either refused
study participation (n= 33, 15.6%), guardians could not be reached
within 7 days of antipsychotic initiation (n = 31, 15.7%), or they
fulfilled the remaining exclusion criteria (n= 10, 4.7%). Further-
more, 8 patients were excluded due to > 24 months of antipsychotic
treatment or initiation of clozapine treatment (Fig 1).
Baseline characteristics
The full ITT study sample consisted of 130 children and ado-
lescents (mean age, 15.3 – 3.0; range, 5–19 years; 85.4% post-
pubertal) diagnosed with SCZ-S (n= 42, 32.3%) or PsyNOS
(n= 88, 67.7%) (Table 1). In the SCZ-S group, most patients had a
schizophrenia diagnosis (n= 36, 85.7%), and a few had either
schizoaffective disorder (n= 3, 7.1%) or schizophreniform disorder
(n= 3, 7.1%). In the PsyNOS group, all patients had a diagnosis of
psychosis not otherwise specified, except for one patient with brief
psychotic disorder. The majority of the sample was male (59.2%),
and most were non-Caucasian (65.1%). The mean socioeconomic
status was 2.7. The majority of the sample had a psychiatric family
history (61%), the most common diagnosis being depression
(18.7% first degree, 22.7% second degree), and 74.6% were inpa-
tients at baseline and, overall, patients scored between markedly
and severely ill (mean CGI-S, 5.6 – 0.9; CGAS, 34.0 – 9.4).
Compared with those with PsyNOS, SCZ-S youth were older
(16.4– 2.1 vs. 14.8– 3.2, p= 0.0090) and less likely to be Caucasian
(19.1% vs. 42.5%, p= 0.009) (Table 1). At baseline, SCZ-S patients
had significantly higher CGI-S scores (6.0– 0.9 vs. 5.5– 0.8, p=
0.0018) and lower CGAS scores (29.6– 9.2 vs 36.1– 8.9, p=
0.0002). According to categorical CGAS criteria, almost all patients
in both groups (97.6% vs. 96.6%) were severely ill. Although not
significant in the ITT-sample ( p= 0.054), in the mITT sample, the
SCZ-S group had a lower mean number of psychiatric comorbidities
(0.4– 0.5 vs. 0.7–0.9, p=0.031) (Table 1).
Of the 106 patients with at least one postbaseline assessment
(mITT sample), 38 (35.8%) had SCZ-S and 68 (64.2%) had Psy-
NOS. Comparing the 24 patients who dropped out of the study after
baseline with the 106 who had at least one baseline visit on all
baseline characteristics (see Table 1), no significant group differ-
ences were found, indicating that the patients with follow-up data
were representative of the entire sample.
Psychotropic treatment characteristics
The majority of the sample was antipsychotic naive (SCZ-S
73.8% vs. PsyNOS 78.4%) as well as being naı¨ve to any psycho-
tropic medication exposure (SCZ-S 66.7%; PsyNOS 61.4%; Table
2). The mean duration since first antipsychotic exposure was
0.3 – 0.7 years, and the mean duration of lifetime antipsychotic
exposure was 1.7 – 4.5 months, without group differences. Ris-
peridone was the most frequently initiated antipsychotic (47.7%),
followed by olanzapine (19.2%), aripiprazole (14.6%), and que-
tiapine (11.5%), whereas ziprasidone was the least used (6.9%).
Except for more patients with SCZ-S than with PsyNOS being
started on olanzapine (38.1% vs. 10.2%, p < 0.0001), treatments did
not significantly differ across the two groups. Results were similar
in the mITT group (Table 3).
Baseline ratings of adverse effects measured on the TESS
showed only a difference between the two groups on psychomotor
activation/retardation, with SCZ-S patients having more psycho-
motor retardation (41.5% vs. 15.4%, p= 0.002 in ITT) and PsyNOS
patients reporting more psychomotor activation (11.5% vs. 0%,
p = 0.03 in ITT). Results were similar in the mITT group (Table 4).
Furthermore, the two groups did not differ on body weight, body
mass index (BMI) z score, blood levels of glucose and lipid me-
tabolism, or prolactin and adverse effect scales (Table 5), except for
a higher HOMA-IR value in the SCZ-S group in the ITT sample
(71.0 – 34.5 vs. 57.5 – 36.6, p= 0.047).
Primary outcomes: Mean CGI-I scores and categorical
CGAS based outcomes
After 12 weeks of antipsychotic treatment, SCZ-S patients im-
proved significantly less than PsyNOS patients on the CGI-I
(2.9 – 0.4 vs. 2.1 – 0.3, p= 0.0012; Table 6). Moreover, although
both groups had significantly improved CGAS ( p < 0.0001), fewer
SCZ-S patients reached a mildly ill or better CGAS-based outcome
(0% vs. 7.4%), and more had a severely ill or worse CGAS-based
outcome (65.8% vs. 42.7%), p= 0.40; Fig. 2).
Secondary outcomes: CGI-S and CGAS end-point
and change scores, and CGI-I based responder status
Although both groups improved significantly on the CGI-S
( p < 0.0001), SCZ-S patients improved significantly less thanFIG. 1. Patient flow.
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PsyNOS patients (-1.0 – 0.3 vs. -1.6 – 0.3, p = 0.036) and the
end-point CGI-S score was significantly higher (4.6 – 0.3 vs.
4.0 – 0.3, p = 0.036) (Table 6). Similarly, CGAS scores im-
proved significantly less in SCZ-S patients than in PsyNOS
patients (12.0 – 3.3 vs. 18.0 – 2.8, p = 0.031), and the end-point
CGAS score was significantly lower (46.3 – 3.3 vs. 52.3 – 2.8,
p = 0.031). Finally, at a trend level, fewer patients with SCZ-S
were treatment responders, defined by a score of much or very
much improved on the CGI-I scale (44.7% vs. 62.7%, p = 0.067)
(Table 6).
Secondary Outcomes: Treatment discontinuation,
nonadherence, and length of hospital admission
Information on medication continuation was available for
95.4% of the sample. During the 12 weeks of the study, 40.3%
Table 1. Baseline Characteristics ITT Sample and Group Comparisons of Psychosis Not Otherwise Specified (NOS)
versus Schizophrenia-Spectrum Disorder for Both the Intent-to-Treat (ITT) and Modified ITT (mITT) Samples
Baseline characteristic
No. of
patients
with data
Total
(n = 130)
Schizophrenia-
spectrum
(n= 42)
Psychosis
NOS (n= 88)
p Value
ITT
p Value
mITT
(n= 106a)
Demographic characteristics
Age (years, mean –SD) 130 15.3 – 3.0 16.4 – 2.1 14.8 – 3.2 0.0040 0.012
Postpubertal status - n post (%) 130 111 (85.4) 40 (95.2) 71 (80.7) 0.033 0.079
Male gender - n (%) 130 77 (59.2) 29 (69.1) 48 (54.6) 0.12 0.21
Caucasian etnicity - n (%) 129 45 (34.9) 8 (19.1) 37 (42.5) 0.009 0.004
Inpatient - n (%) 130 97 (74.6) 37 (88.1) 60 (68.2) 0.017 0.023
SES (Hollingshead 1-5, mean – SD) 108 2.7 – 0.9 2.8 – 0.8 2.7 – 0.9 0.64 0.44
Primary diagnosis - n (%) 130 < 0.0001 < 0.0001
Schizophrenia 36 (27.7) 36 (85.7) 0
Schizoaffective disorder 3 (2.3) 3 (7.1) 0
Schizophreniform disorder 3 (2.3) 3 (7.1) 0
Psychosis not otherwise specified 87 (66.9) 0 87 (98.9)
Brief psychotic disorder 1 (0.8) 0 1 (1.1)
Family history - n (%)
Any psychiatric first or second degree family member 77 47 (61.0) 13 (54.2) 34 (64.2) 0.41 0.36
Schizophrenia-spectrum: First degree member 75 3 (4) 1 (4.4) 2 (3.9) 1.0 0.55
Schizophrenia-spectrum: Second degree member 75 14 (18.7) 7 (30.4) 7 (13.5) 0.082 0.11
Bipolar-spectrum: First degree member 76 5 (6.6) 1 (4.4) 4 (7.6) 1.0 1.0
Bipolar-spectrum: Second degree member 76 4 (5.3) 1 (4.4) 3 (5.7) 1.0 1.0
Depression-spectrum: First degree member 75 14 (18.7) 2 (8.7) 12 (23.1) 0.20 0.20
Depression -spectrum: Second degree member 75 17 (22.7) 7 (30.4) 10 (19.2) 0.29 0.37
Psychiatric comorbidity
Number of comorbidities (mean –SD) 130 0.6 – 0.8 0.4 – 0.5 0.7 – 0.9 0.054 0.031
Any comorbidity - n (%) 130 61 (46.9) 16 (38.1) 45 (51.1) 0.16 0.11
Substance abuse disorders - n (%) 130 22 (16.9) 9 (21.4) 13 (14.8) 0.34 0.35
Attention-deficit/hyperactivity disorder - n (%) 130 17 (13.1) 3 (7.1) 14 (15.9) 0.27 0.16
Disruptive behavior disorderb- n (%) 130 12 (9.2) 1 (2.4) 11 (12.5) 0.10 0.093
Generalized anxiety disorder, panic disorder - n (%) 130 13 (10.0) 1 (2.4) 12 (13.6) 0.060 0.093
Depressive disorder c - n (%) 130 8 (6.2) 0 (0.0) 8 (9.1) 0.053 0.048
Mental retardation - n (%) 130 6 (4.6) 1 (2.4) 5 (5.7) 0.66 0.42
Obsessive compulsive disorder – no. (%) 130 6 (4.6) 2 (4.8) 4 (4.6) 1.0 1.0
Autism spectrum disorder – no. (%) 130 6 (4.6) 0 (0.0) 6 (6.8) 0.18 0.16
Clinical Global Impressions-Severity
(CGI-S) score (mean – SD)
128 5.6 – 0.9 6.0 – 0.9 5.5 – 0.8 0.0018 0.0034
CGI-S categorical - n (%) 128 0.045 0.040
Mild CGI-S: £mildly ill 1 (0.8) 0 1 (1.2)
Moderate CGI-S: moderate or markedly ill 44 (34.4) 9 (21.4) 35 (40.7)
Severe CGI-S:‡ severely ill 83 (64.8) 33 (78.6) 50 (58.1)
Children’s Global Assessment Scale
(CGAS) score (mean – SD)
129 34.0 – 9.4 29.6 – 9.2 36.1 – 8.9 0.0002 0.0004
CGAS categorical (<50, 51–70, >70) - n (%) 129 1.0 1.0
Mild (>70) 0 (0.0) 0 0 (0)
Moderate (51–70) 4 (3.1) 1 (2.4) 3 (3.5)
Severe (£50) 125 (96.9) 41 (97.6) 84 (96.6)
Significant differences at p£ 0.05 have been bolded.
aIncluding only patients with at least one follow-up assessment (Psychosis NOS = 68, Schizophrenia-spectrum= 38); mITT p values are shown for
baseline variables in order to present variables that were significantly different across groups, which were adjusted for in the outcome analyses.
bIncluding oppositional defiant disorder, conduct disorder, intermittent explosive disorder, and impulse control disorder not otherwise specified.
cIncluding major depressive disorder, depression not otherwise specified, and adjustment disorder.
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discontinued medication, either as decided by the physician be-
cause of lack of efficacy or side effects, or because of the family’s/
patient’s choice. Although SCZ-S and PsyNOS subjects did not
differ regarding all-cause discontinuation (40.5% vs. 40.3%,
p = 0.49), more patients with SCZ-S discontinued their antipsy-
chotic because of inefficacy (19.5% vs. 7.4%, p = 0.063) (Table 7).
There was no difference between SCZ-S and PsyNOS patients
regarding discontinuation because of intolerability (12.2% vs.
12.4%, p = 0.97), nonadherence (29.3% vs. 30.9%, p = 0.88), or
length of hospital stay (21.8– 5.7 days vs. 24.3 – 4.8 days, p= 0.65).
Table 2. Antipsychotic Treatment Characteristics in the Intent-to-Treat (ITT) Sample
Antipsychotic (AP) treatment
characteristics in the ITT sample
No. of
patients
with data
Total
(n= 130)
Schizophrenia-
spectrum
(n= 42)
Psychosis not
otherwise specified
(NOS) (n = 88)
p Value
ITT
Years since first psychotropic treatment (mean – SD) 130 0.7 – 1.8 1.0 – 2.7 0.6 – 1.3 0.75
Psychotropic treatment naı¨ve - n (%) 130 82 (63.1) 28 (66.7) 54 (61.4) 0.56
Prior no. of AP trials (mean –SD) 130 0.5 – 0.8 0.7 – 1.2 0.4 – 0.6 0.20
Years since first AP treatment (mean –SD) 130 0.3 – 0.7 0.4 – 1.0 0.2 – 0.6 0.33
Lifetime AP duration (months, mean– SD) 130 1.7 – 4.5 2.4 – 6.3 1.3 – 3.4 0.32
AP treatment naı¨vea - n (%) 130 100 (76.9) 31 (73.8) 69 (78.4) 0.56
Naive patients, lifetime days on AP (mean – SD) 100 1.3 – 3.5 2.2 – 4.8 0.9 – 2.5 0.08
AP treatment history, restartedb- n (%) 130 12 (9.2) 2 (4.8) 10 (11.4) 0.34
History patients, lifetime days on AP (mean –SD) 12 177– 141.4 359.3– 99.5 140.7 – 120 0.038
AP switch - n (%) 130 18 (13.9) 9 (21.4) 9 (10.2) 0.08
Switch patients, lifetime days on AP (mean – SD) 18 247.1– 255.6 258.5– 324.5 235.7– 182.2 0.86
AP treatment choice - n (%) 130
Aripiprazole 130 19 (14.6) 5 (11.9) 14 (15.9) 0.61
Olanzapine 130 25 (19.2) 16 (38.1) 9 (10.2) < 0.0001
Quetiapine 130 15 (11.5) 3 (7.1) 12 (13.6) 0.55
Risperidone 130 62 (47.7) 15 (35.7) 47 (53.4) 0.059
Ziprasidone 130 9 (6.9) 6 (6.8) 3 (7.1) 1.0
Significant differences at p £ 0.05 have been bolded.
aAP treatment naı¨ve: £ 7 days of lifetime AP exposure.
bAP treatment history, restarted: AP restarted after at least a 4 week gap.
Table 3. Psychotropic Treatment Characteristics (Modified Intent-to-Treat [mITT])
Psychotropic treatment characteristics
No. of
patients
with data
Total
(n= 106)
Schizophrenia-
spectrum
(n= 38)
Psychosis not
otherwise specified
(NOS) (n = 68)
p Value
mITT
adjusteda
Treatment history
Years since first psychotropic treatment (mean – SD) 106 0.8 – 2.0 1.0 – 2.8 0.7 – 1.4 0.049
Psychotropic treatment-naı¨ve - n (%) 106 66 (62.3) 25 (65.8) 41 (60.3) 0.057
Prior # of antipsychotic trials (mean –SD) 106 0.5 – 0.9 0.7 – 1.2 0.4 – 0.6 0.10
Years since first antipsychotic treatment (mean – SD) 106 0.3 – 0.8 0.4 – 1.0 0.3 – 0.7 0.18
Lifetime antipsychotic duration (months, mean – SD) 106 1.7 – 4.5 2.1 – 5.6 1.5 – 3.7 0.13
Antipsychotic treatment naı¨ve - n (%) 106 83 (78.3) 28 (73.7) 55 (80.9) 0.11
Antipsychotic treatment history, restarted - n (%) 106 9 (8.5) 2 (5.3) 7 (10.3) 0.34
Antipsychotic switch - n (%) 106 14 (13.2) 8 (21.1) 6 (8.8) 0.013
Antipsychotic treatment choice - n (%) 106
Aripiprazole 15 (14.2) 4 (10.5) 11 (16.2) 0.56
Olanzapine 22 (20.8) 15 (39.5) 7 (10.3) 0.032
Quetiapine 14 (13.2) 3 (7.9) 11 (16.2) 0.49
Risperidone 50 (47.2) 14 (36.8) 36 (52.9) 0.15
Ziprasidone 5 (4.7) 2 (5.3) 3 (4.4) 0.49
Non-antipsychotic co-medications
Total number of co-medications 3 months (mean – SD) 0.8 – 0.8 0.6 – 0.8 0.9 – 0.8 0.28
Specific co-medications 3 months - n (%)
None 42 (40.4) 18 (48.7) 24 (35.8) 0.42
Antidepressant 26 (25.0) 5 (13.5) 21 (31.3) 0.42
Anxiolytic/hypnotic 17 (16.4) 4 (10.8) 13 (19.4) 0.13
Mood stabilizer 12 (11.5) 7 (18.9) 5 (7.5) 0.14
Psychostimulant 5 (4.8) 1 (2.7) 4 (6.0) 0.42
Anticholinergic 14 (13.5) 6 (16.2) 8 (11.9) 0.61
Significant differences at p £ 0.05 have been bolded.
aAdjustment variables for p values in the mITT analyses of antipsychotic choice: Age, Caucasian, inpatient status, number of comorbidities, comorbid
depression, Children’s Global Assessment Scale (CGAS) baseline, Clinical Global Impressions – Severity (CGI-S) baseline.
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Adverse effects at 3 month follow-up
Measured with the TESS (Table 4), SARS, BARS, and AIMS
(Table 5), there were no differences between the two diagnostic
groups in reported or rated adverse effects at 3 months LOCF.
Similarly, there were also no differences between the two diag-
nostic groups in weight, BMI z score, and laboratory test results,
with the exception of significantly higher LDL (40.6 – 8.6 vs.
27.6 – 8.0, p= 0.019) and nearly significantly higher HOMA-IR
(1.3 – 0.6 vs. 0.4 – 0.5, p= 0.054) in the SCZ-S group (Table 5).
Discussion
This naturalistic study comparing 12-week outcomes of anti-
psychotic treatment within the first 2 years of illness across 130
youth with a DSM-IV diagnosis of SCZ-S or PsyNOS supported
our initial hypotheses of greater treatment responsiveness in the
PsyNOS group. The main findings of this study were: 1) SCZ-S
patients had significantly greater illness severity and lower func-
tioning than PsyNOS patients at both baseline and follow-up; and
2) although CGI-S and CGAS scores improved significantly in both
diagnostic groups, SCZ-S patients experienced significantly less
improvement in illness severity and functioning when adjusting for
baseline differences.
Schizophrenia is a more severe illness than PsyNOS, which is
reflected in the current study by the comparison of both baseline
and follow-up data. This finding was expected and is consistent
with other studies in youth (McClellan et al. 1999; Helgeland and
Torgersen 2005; Hassan and Taha 2011; Clemmensen et al. 2012).
For example, our results in the SCZ-S group are very comparable to
the 8 week results from the Treatment of Early Onset Schizophrenia
Spectrum Disorders (TEOSS) study, in which 44.0% were much or
very much improved on the CGI-I (Sikich et al. 2008), compared
with 44.7% in our sample. However, studies in youth with psy-
chosis NOS are scarce, and direct comparisons of early treatment
outcomes with a concurrently treated group of SCZ-S patients
are rare. Although patients with PsyNOS are sometimes included
in studies of first episode psychosis, the results are rarely reported
separately by diagnosis, confounding results in patients with
schizophrenia. Therefore, future studies that include both SCZ-S
and PsyNOS patients should present results for both subgroups. In
the few child and adolescent studies with separate results for each
diagnostic group or with a specific focus on PsyNOS, the sample
size of the PsyNOS group was generally small (McClellan et al.
1999; Nicolson et al. 2001; Correll et al. 2005, 2008; Fraguas et al.
2008; Hassan and Taha 2011) with numbers of PsyNOS patients
ranging between 6 and 26. To our knowledge, the present study is
Table 4. Baseline and 3-Month Period Prevalence Rates of Relevant Adverse Effects Measured
with the Treatment Emergent Symptoms Scale
Baseline 12 weeks LOCF
Adverse
effects n (%)
No. of
patients
with data
Total
(n= 130)
Schizophrenia-
spectrum
(n= 42)
Psychosis
NOS
(n = 88)
p value
mITT
(n= 106)a
No. of
patients
with data
Total
(n = 130)
Schizophrenia-
spectrum
(n = 42)
Psychosis
NOS
(n = 88)
p value
mITT, adj.
(n= 106)a
Agitation 110 11 (10.0) 4 (10.3) 7 (9.9) 1.0 102 4 (3.9) 1 (2.7) 3 (4.6) 0.94
Restlessness 110 35 (31.8) 9 (23.7) 26 (36.1) 0.15 101 11 (10.9) 2 (5.4) 9 (14.1) 0.39
Psychomotor
activation
119 9 (7.6) 0 (0) 9 (11.5 0.048 102 6 (5.9) 0 (0) 6 (9.2) 0.086
Psychomotor
retardation
119 29 (24.4) 17 (41.5) 12 (15.4) 0.001 102 34 (33.3) 13 (35.1) 21 (32.3) 0.27
Malaise 111 30 (27.0) 11 (28.2) 19 (26.4) 0.65 102 19 (18.6) 3 (8.1) 16 (24.6) 0.12
Increased sleep 118 16 (13.6) 5 (12.2) 11 (14.3) 0.70 103 36 (35.0) 11 (29.7) 25 (37.9) 0.89
Decreased sleep 118 35 (29.7) 10 (24.4) 25 (32.5) 0.37 103 8 (7.8) 2 (5.4) 6 (9.1) 0.97
Rigidity 111 2 (1.8) 2 (2.6) 1 (1.4) 1.0 101 4 (4.0) 4 (10.8) 0 (0) 0.47
Tremor 111 9 (8.1) 3 (7.7) 6 (8.3) 1.0 100 10 (10.0) 3 (8.1) 7 (11.1) 0.99
Dystonia 111 0 (0) 0 (0) 0 (0) 1.0 97 0 (0) 0 (0) 0 (0) 1.0
Akathisia 111 1 (0.9) 0 (0) 1 (1.4) 1.0 99 3 (3.0) 0 (0) 3 (4.8) -
Dyskinesia 111 0 (0) 0 (0) 0 (0) 1.0 99 4 (4.0) 2 (5.6) 2 (3.2) 0.47
Syncope 111 21 (18.9) 5 (12.8) 16 (22.2) 0.12 99 15 (15.2) 3 (8.3) 12 (19.1) 0.92
Dry mouth 109 19 (17.4) 6 (15.8) 13 (18.3) 0.81 99 24 (24.2) 10 (27.8) 14 (22.2) 0.37
Blurry vision 110 12 (10.9) 5 (12.8) 7 (9.9) 0.32 99 8 (8.1) 2 (5.6) 6 (9.5) 0.97
Constipation 110 12 (10.9) 3 (7.7) 9 (12.7) 0.32 99 11 (11.1) 3 (8.3) 8 (12.7) 0.74
Nausea 110 3 (2.7) 0 (0) 3 (4.2) 0.54 100 3 (3.0) 2 (5.4) 1 (1.6) -
Vomiting 110 2 (1.8) 0 (0) 2 (2.8) 0.54 99 2 (2.0) 1 (2.8) 1 (1.6) -
Diarrhea 110 4 (3.6) 0 (0) 4 (5.6) 0.29 99 2 (2.0) 1 (2.8) 1 (1.6) -
Menstrual
disturbanceb
41 10 (24.4) 3 (25.0) 7 (24.1) 1.0 34 14 (41.2) 4 (40.0) 10 (41.7) 0.74
Decreased libidoc 96 6 (6.3) 3 (8.1) 3 (5.1) 0.37 88 10 (11.4) 5 (14.7) 5 (9.3) 0.99
Impaired sexual
performancec
96 4 (4.2) 1 (2.7) 3 (5.1) 1.0 88 9 (10.2) 5 (14.7) 4 (7.4) 0.62
Increased appetite 117 23 (19.7) 8 (19.5) 15 (19.7) 0.49 102 46 (45.1) 16 (43.2) 30 (46.2) 0.57
Decreased
appetite
117 25 (21.4) 7 (17.1) 18 (23.7) 0.61 102 8 (7.8) 2 (5.4) 6 (9.2) 0.97
Significant differences at p£ 0.05 have been bolded.
aIncluding only patients with at least one follow-up assessment (psychosis NOS= 68, schizophrenia-spectrum= 38).
bThe analyses on menstrual disturbance are restricted to postpubertal females.
cThe analyses on decreased libido and impaired sexual performance are restricted to postpubertal patients.
LOCF, last-observation-carried-forward; NOS, not otherwise specified; mITT, modified intent-to-treat.
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the largest to date comparing child and adolescent PsyNOS patients
with early-onset schizophrenia youth using the same assessment
measures at baseline and follow-up with follow-up data in as many
as 68 PsyNOS patients.
Studies in adults also reported that PsyNOS patients had better
outcomes than patients with schizophrenia (Kendler and Walsh
1995; Harrison et al. 2001; Jobe and Harrow 2005; Crespo-Facorro
et al. 2007; Simonsen et al. 2010; Crespo-Facorro et al. 2013; Diaz
et al. 2013; Pelayo-Teran et al. 2014). However, even in adults,
such comparative studies are sparse, and generally have the same
limitations as studies in the child and adolescent population; either
small sample sizes or lack of differentiation among the different
diagnostic first-episode psychosis subgroups. The Genetic Risk and
Outcome of Psychosis (GROUP) study is an exception to the
sample size limitation; the study compared 1064 patients with
nonaffective psychotic disorders (among these were 117 with
PsyNOS and 731 with schizophrenia) and found PsyNOS patients
to have higher remission rates (23%) than SCZ patients (14%),
shorter duration of illness, better functioning, and less severe
psychopathology (Korver-Nieberg et al. 2011). Additionally, an
Asian study of 195 patients with PsyNOS found higher rates of
recovery in PsyNOS than in schizophrenia (Verma et al. 2012).
Notably, however, whenever patients with schizoaffective disorder
or psychotic mood disorders were included, PsyNOS patients had
outcomes in between those for schizophrenia and psychotic mood
disorders, performing worse than those with mood disorders with
psychosis, both in studies of youth (McClellan &McCurry, 1999b)
and in studies of adults (Verma et al. 2012).
Importantly, short-term outcome benefits in patients with Psy-
NOS seem to translate into longer-term advantages, and studies in
adults found remission rates > 50% (Chaturvedi and Sahu 1986;
Sivakumar and Chandrasekaran 1993).
Table 6. Efficacy Outcomes (Modified Intent-to-Treat [mITT] Sample)
Efficacy outcomesa
No. of
patients
with data
Total
(n = 106)
Schizophrenia-
spectrum
(SCZ-S) (n = 38)
Psychosis not
otherwise specified
(PsyNOS) (n= 68)
p value,
mITT,
adjustedb
Co-primary outcomes
Clinical Global Impressions-Improvement (CGI-I) 3mo.
mITT last observation carried forward (LOCF)
(least squares mean [LSM] –SE)
105 2.4 – 0.3 2.9 – 0.4 2.1 – 0.3 0.012
Categorical Children’s Global Assessment
Scale (CGAS) outcome – n (%)
106 0.040
Mild: > 70 5 (4.7) 0 (0) 5 (7.4)
Moderate: 51–70 47 (44.3) 13 (34.2) 34 (50.0)
Severe: £ 50 54 (50.9) 25 (65.8) 29 (42.7)
Secondary outcomes
Change in CGI-S scorec (LSM – SE) 106 - 1.4 – 0.3 - 1.0 – 0.3 - 1.6 – 0.3 0.036d
CGI-S end-point (LSM – SE) 106 4.2 – 0.3 4.6 – 0.3 4.0 – 0.3 0.036d
CGI-I based response (much or very much
improved), – n (%)
105 59 (56.2) 17 (44.7) 42 (62.7) 0.067
Change in CGAS c (LSM –SE) 106 15.9 – 2.7 12.0 – 3.3 18.0 – 2.8 0.031d
CGAS end-point (LSM– SE) 106 50.1 – 2.7 46.3 – 3.3 52.3 – 2.8 0.031d
Significant differences at p£ 0.05 have been bolded.
aData are presented as number of patients (percent) or adjusted least square means– standard error for each column.
bAdjustments were made according to differences at baseline in the mITT sample between PsyNOS and SCZ-S of p value< 0.05. Outcome analyses
were adjusted for age, Caucasian y/n, inpatient status, olanzapine use, number of comorbidities, comorbid depression, CGAS baseline, CGI-S baseline,
and SCZ-S/PsyNOS.
cChanges in CGI-S and CGAS scores from baseline to 12 weeks within groups were significant at p < 0.0001.
dAnalyses conducted with baseline values as covariates.
FIG. 2. Categorical Children’s Global Assessment Scale (CGAS) at baseline and follow-up.
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In youth, however, the longer-term outcomes of patients with
PsyNOS may be more heterogeneous. The few small studies point
to remission rates or CGAS-defined good outcome between 20%
and 68% (McClellan and McCurry 1999; Nicolson et al. 2001;
Correll et al. 2008; Hassan and Taha 2011). As our co-primary
outcome, we assessed categorical CGAS ratings, using the same
cutoffs for good, moderate, and poor outcome as selected in a recent
review on 21 studies in patients with early-onset schizophrenia and
other psychotic disorders (Clemmensen et al. 2012). In terms of
poor outcome, our results were quite similar: In the SCZ-S group,
Clemmensen et al. found 60.1%with poor outcome, compared with
66% in our study. For the group of mixed psychotic disorders,
Clemmensen et al. reported 46.8% with poor outcome and we
found 42.7% in the PsyNOS group. In the pooled analysis, more
individuals were reported to have a good outcome (i.e., 15.4% in
SCZ-S and 19.6% in groups of mixed psychotic disorders), whereas
in our sample, we found rates of 0%with good outcome in the SCZ-
S group and only 7.4% in the PsyNOS, probably because some
patients needing > 12 weeks to improve substantially. These find-
ings indicate that poor long-term outcome might be predictable
from the early treatment phase, whereas transition from moderate
to good outcome may require more time.
Although both patients with SCZ-S and those with PsyNOS
improved during the 3 month follow-up, it is concerning that 40.8%
of the patients in our study discontinued antipsychotics in the first
12 weeks of treatment, either because of patient/family choice
(18.0%) or because of the practitioner’s choice based on side ef-
fects (12.3%) or lack of efficacy (11.5%). This finding is very
similar to findings from the TEOSS study, which reported all-cause
discontinuation in 39.7% of youth after 8 weeks of treatment, with
13.8% discontinuing because of lack of efficacy (Sikich et al.
2008). It is even more concerning that patients with the most severe
disorder, schizophrenia, more often experienced a lack of efficacy,
even in this group of patients who were mostly previously anti-
psychotic naı¨ve. Notably, full nonadherence, a clear mediator of
poorer outcomes (Kane et al. 2013), was present in 22.0% of our
sample, compared with 11.2% in the TEOSS sample (Sikich et al.
2008), but we also had antipsychotic blood levels available to
supplement patient and caregiver data to identify nonadherence.
These data indicate that clinicians need to pay attention to overt and
covert nonadherence in the early illness phase in youth with SCZ-S.
Our finding that the PsyNOS group experienced significantly
better outcomes on the CGI-I, CGI-S, and CGAS and had less
discontinuation as a result of inefficacy than the SCZ-S group
suggests that earlier treatment of people with psychotic disorders,
including prior to having developed full schizophrenia, provides a
chance for better outcomes. To what degree this translates into the
ability to prevent transition from PsyNOS to full-blown schizo-
phrenia (Correll et al. 2005, 2008) requires further study, especially
in youth, in whom the diagnosis of PsyNOS is more common than
that of schizophrenia. Although the present study followed patients
only for 12 weeks, data have accumulated that symptomatic im-
provement after as little as a few weeks predicts ultimate outcomes
at 3 months and beyond (for review, see Correll et al. [2011a],
including in adolescents [Correll et al. 2013; Stentebjerg-Olesen
et al. 2013]). Therefore, our findings of better outcomes in patients
with PsyNOS than in schizophrenia patients stress the need for
effective interventions in the early phases of psychotic disorders.
However, more research is needed into the group of patients with
poor early outcomes, trying to identify effective treatment strate-
gies that may alter the trajectory of the illness at this early time. Even
though most patients with PsyNOS will likely not go on to develop
schizophrenia, treating psychosis quickly and effectively is impor-
tant in order to minimize long-term disability. As mentioned, one
study found 38% of youth with PsyNOS to be chronically impaired
after 2 years, even without transitioning into other disorders
(McClellan et al. 1999). Nevertheless, the fact that in our study both
diagnostic groups had similar adverse effect burdens underscores that
for patients with PsyNOS long-term antipsychotic treatment needs to
be balanced against the potential for adverse effects, and that pro-
active adverse effect monitoring and management of antipsychotics
is essential (Correll et al. 2008; Maayan and Correll 2011).
Limitations
The results of this study have to be interpreted within its limi-
tations. These include the nonrandomized design, naturalistic
treatment setting and choice, lack of research diagnostic interviews
Table 7. Effectiveness Outcomes (Intent-to-Treat [ITT] Sample)
Effectiveness outcomesa
No. of
patients
with data
Total
(n= 130)
Schizophrenia-
spectrum
(SCZ-S) (n= 42)
Psychosis not
otherwise specified
(PsyNOS) (n= 88)
Adjusted
p value
ITTb
No. inpatient days on antipsychotics during
3 month trialc (least squares mean [LSM] – SE)
79 23.3 – 4.4 21.8 – 5.7 24.3 – 4.8 0.65c
Any nonadherence - n (%) 122 37 (30.3) 12 (29.3) 25 (30.9) 0.57
Partial adherenced 10 (8.2) 3 (7.3) 7 (8.6)
Full nonadherencee 27 (22.1) 9 (22.0) 18 (22.2)
All-cause discontinuation- n (%) 124 50 (40.3) 17 (40.5) 33 (40.3) 0.53
Discontinuation because of inefficacy - n (%) 122 14 (11.5) 8 (19.5) 6 (7.4) 0.063
Discontinuation because of intolerability - n (%) 122 15 (12.3) 5 (12.2) 10 (12.4) 0.94
Discontinuation because of patient/family choice - n (%) 122 22 (18.0) 6 (14.6) 16 (19.8) 0.29
Loss of contact - n (%) 122 7 (5.4) 0 7 (8.0) unstable
aData are presented as number of patients (percent) or adjusted least square means– standard error for each column.
bAdjustments were made according to differences at baseline in the ITT sample between PsyNOS and SCZ-S of p value< 0.05. Outcome analyses of
the ITT-sample were adjusted for age, pubertal status, Caucasian y/n, inpatient-status, olanzapine use, Children’s Global Assessment Scale (CGAS)
baseline, Clinical Global Impressions – Severity (CGI-S) baseline, and SCZ-S/PsyNOS.
cThis analysis was restricted to patients who were inpatients at baseline. The adjustments were PsyNOS/SCZ-S, age, Caucasian y/n, comorbid anxiety
disorder, olanzapine use, CGAS, and CGIS-baseline.
dInterrupting medication taking for 1–6 days.
eInterrupting medication taking ‡ 7 days or antipsychotic blood level of zero.
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and specific psychopathology ratings, the still relatively small
sample size, and short duration of follow-up. Further, more patients
with SCZ-S than PsyNOS consented to the study, which could have
introduced a bias. Additionally, we did not have data on long-term
diagnostic outcome data in the PsyNOS group, which could indi-
cate that the better initial outcome in this sample was driven by a
subgroup of patients who ultimately turned out to have mood dis-
orders with psychosis. Moreover, we focused only on global ef-
fectiveness and efficacy measures of all antipsychotics combined
and did not formally assess nonpharmacologic treatments. Also,
18.5% of the sample did not return for follow-up visits.
High attrition is a well-known problem in psychiatric research
(Martin et al. 2006; Thompson et al. 2011; Jorgensen et al. 2014).
Our attrition after baseline were rather low, and we were able to
capture information on medication persistence and reasons for
treatment discontinuation in 124 (95.4%) of 130 patients.
Conclusion
In this naturalistic study with clinician’s choice antipsychotic
treatment, youth with SCZ-S disorders had both greater illness
severity and lower functioning at baseline as well as after 12 weeks
of antipsychotic treatment relative to PsyNOS patients, even
though both groups improved significantly. Treatment discontinu-
ation was common within 12 weeks in both groups of patients.
These data suggest that early treatment and intervention in youth
during the initial stages of psychotic disorders are critical for in-
creasing the chances of improving the symptomatic and functional
outcome in this vulnerable population. These data also underscore
the high percentage of noncompliance and discontinuation with
antipsychotic treatment early during the illness course.
Clinical Significance
Our findings indicate that clinicians should comprehensively
screen for the presence of psychotic symptoms in children and
adolescents and address full psychotic disorders as early as possi-
ble. Treating patients in the early phases of psychosis may lead to
better short and long-term outcomes, reducing the risk of more
chronic impairment. Following this line of argument, identification
of prodromal youth and intervention with the lowest risk treatment
options during that earliest stage of illness development should also
be aimed for (Correll et al. 2010; Schimmelmann et al. 2013b;
Stafford et al. 2013). Antipsychotics, however, should likely be
avoided during the clinical high-risk stage, as the majority of
people with attenuated positive symptoms will not go on to develop
full-blown psychosis (Fusar-Poli et al. 2012), which is also true for
adolescents (Cornblatt et al. 2015). The clinical high-risk stage, or
attenuated psychosis syndrome as per Diagnostic and Statistical
Manual of Mental Disorders, 5th ed. (DSM-V), is differentiated
clinically from PsyNOS by the absence of threshold psychotic
symptoms; that is, delusions, hallucinations, or disorganized thought/
speech (American Psychiatric Association 2013). Finally, proactive
monitoring of side effects and efficacy along with careful risk–ben-
efit evaluation of treatment choice continue to be extremely impor-
tant in this patient population because of the high likelihood of
nonpersistence, with a relatively high incidence of side-effects and
lack of efficacy (Correll 2008; Maayan and Correll 2011).
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